Genetic toxicity in relation to receptor-mediated carcinogenesis

Related Experiment Video

Updated: Nov 6, 2026

Mutagenesis and Analysis of Genetic Mutations in the GC-rich KISS1 Receptor Sequence Identified in Humans with Reproductive Disorders
12:49

Mutagenesis and Analysis of Genetic Mutations in the GC-rich KISS1 Receptor Sequence Identified in Humans with Reproductive Disorders

Published on: September 4, 2011

J Ashby1

  • 1Zeneca Central Toxicology Laboratory, Nr Macclesfield, Cheshire, UK.

Mutation Research
|December 1, 1995
PubMed

Insights

Assessing chemical mutagenicity involves DNA mutation and chromosomal aberration tests in cells and rodents. This data, alongside chemical structure analysis, helps determine if a carcinogen is genotoxic or non-genotoxic.

Area of Science:

  • Toxicology
  • Genetics
  • Carcinogenesis

Background:

  • Standardized assays are emerging to evaluate chemical mutagenicity and heritable DNA damage.
  • Genetic toxicity testing in cell cultures and rodents is crucial for carcinogen mechanism assessment.
  • Chemical structure analysis, particularly electrophilicity, aids in distinguishing genotoxic from non-genotoxic carcinogens.

Purpose of the Study:

  • To outline the integrated approach for assessing chemical genetic toxicity and carcinogen mechanisms.
  • To highlight the importance of high-quality genetic toxicity data for informed mechanistic estimations.
  • To illustrate the application of these concepts using specific chemical examples.

Main Methods:

  • In vitro assays for chromosomal aberrations and gene mutations.
  • In vivo rodent studies for genetic toxicity confirmation.
  • Analysis of chemical structure for electrophilic sites.
  • Advanced assays: DNA adducts (32P post-labelling), Comet assay for DNA damage, transgenic rodent mutation assays.
  • Evaluation of carcinogen extent and sites.

Main Results:

  • A consensus is growing on the necessary assays for genetic toxicity evaluation.
  • Integration of assay results, structural analysis, and carcinogenicity data informs mechanism determination.
  • Specific examples (o-anisidine, methyl clophenipate, etoposide, taxol) demonstrate the application of these methods.

Conclusions:

  • High-quality genetic toxicity data is essential for understanding carcinogen mechanisms.
  • Combining multiple data types provides a robust estimation of genotoxic versus non-genotoxic action.
  • Further integration of genetic toxicity data with other toxicological information is needed for new carcinogen assessments.

More Related Videos

The Lambda Select cII Mutation Detection System07:08

The Lambda Select cII Mutation Detection System

Published on: April 26, 2018

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling09:33

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling

Published on: March 20, 2018

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...